Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 8
Submit an article Journal homepage
158
Views
19
CrossRef citations to date
0
Altmetric
Drug Evaluation

Heat-shock protein–peptide complex-96 for the treatment of cancer

Robert J Amato The Methodist Hospital Research Institute, Genitourinary Oncology Program, Houston, Texas, USA +1 713 441 7920; +1 713 441 7911; [email protected]
, DO
Pages 1267-1273 | Published online: 14 Aug 2007

Bibliography

  • PEGGS KS, QUEZADA SA, KORMAN AJ, ALLISON JP: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. (2006) 18:206-213.
  • RITOSSA FA: New puffing pattern induced by temperature shock and DNP in Drosophilia. Experientia (1962) 18:571-573.
  • SRIVASTAVA PK: Immunotherapy for human cancer using heat shock protein–peptide complexes. Curr. Oncol. Rep. (2005) 7:104-108.
  • ZHU X, ZHAO X, BURKHOLDER WF et al.: Structural analysis of substrate binding by the molecular chaperone DnaK. Science (1996) 272:1606-1614.
  • MACARY PA, JAVID B, FLOTO RA et al.: HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity (2004) 20:95-106.
  • LINDEROTH NA, POPOWICZ A, SASTRY S: Identification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen GP96 (Grp94). J. Biol. Chem. (2000) 272:5472-5477.
  • BAKER-LEPAIN JC, SAARZOTTI M, FIELDS TA, LI CY, NICCHITTA CV: GRP94 (GP96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J. Exp. Med. (2002) 196:1447-1459.
  • GIDALEVITZ T, BISWAS C, DING H et al.: Identification of the N-terminal peptide binding site of glucose-regulated protein 94. J. Biol. Chem. (2004) 279:16543-16552.
  • GOETZ MP, TOFT DO, AMES MM, ERLICHMAN C: The HSP90 chaperone complex as a novel target for cancer therapy. Ann. Oncol. (2003) 14:1169-1176.
  • ISHII T, UDONO H, YAMANO T et al.: Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins HSP70, HSP90, and GP96. J. Immunol. (1999) 162:1303-1309.
  • SPONAAS AM, ZUEGEL U, WEBER S et al.: Immunization with GP96 from Listeria monocytogenes-infected mice is due to N-formylated listerial peptides. J. Immunol. (2001) 167:6480-6486.
  • MENG SD, SONG J, RAO Z et al.: Three-step purification of GP96 from human liver tumor tissues suitable for isolation of GP96-bound peptides. J. Immunol. Methods (2002) 264:29-35.
  • GROSSMANN ME, MADDEN BJ, GAO F et al.: Proteomics shows Hsp70 does not bind peptide sequences indiscriminately in vivo. Exp. Cell Res. (2004) 297:108-117.
  • DEMINE R, WALDEN P: Testing the role of GP96 as peptide chaperone in antigen processing. J. Biol. Chem. (2005) 280:17573-17578.
  • SRIVASTAVA P: Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. (2002) 20:395-425.
  • PRZEPIORKA D, SRIVASTAVA PK: Heat shock protein–peptide complexes as immunotherapy for human cancer. Mol. Med. Today (1998) 4:478-484.
  • SRIVASTAVA PK, AMATO RJ: Heat shock proteins: the “Swiss Army Knife” vaccines against cancers and infectious agents. Vaccine (2001) 19:2590-2597.
  • SRIVASTAVA P: Roles of heat shock proteins in innate and adaptive immunity. Nat. Rev. Immunol. (2002) 2:185-194.
  • BINDER RJ, HAN DK, SRIVASTAVA PK: CD91: a receptor for heat shock protein GP96. Nat. Immunol. (2000) 1:151-155.
  • BASU S, BINDER RJ, RAMALINGAM T, SRIVASTAVA PK: CD91 is a common receptor for heat shock proteins GP96, HSP90, HSP70, and calreticulin. Immunity (2001) 14:303-313.
  • BANERJEE PP, VINAY DS, MATHEW A et al.: Evidence that glycoprotein 96 (B2), a stress protein, functions as a Th2-specific costimulatory molecule. J. Immunol. (2002) 169:3507-3518.
  • BINDER RJ, SRIVASTAVA PK: Essential role of CD91 in re-presentation of GP96-chaperoned peptides. Proc. Natl. Acad. Sci. USA (2004) 101:6128-6133.
  • PARK JE, FACCIPONTE J, CHEN X et al.: Chaperoning function of stress protein grp170, a member of the HSP70 superfamily, is responsible for its immunoadjuvant activity. Cancer Res. (2006) 66:1161-1168.
  • KIM HL, SUN X, SUBJECK JR, WANG XY: Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase IX using heat shock protein 110. Cancer Immunol. Immunother. (2007) 56:1097-1105.
  • LI Y, SUBJECK J, YANG G, REPASKY E, WANG XY: Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine (2006) 24:5360-5370.
  • GOMEZ-GUTIERREZ JG, ELPEK KG, MONTES DE OCA-LUNA R, SHIRWAN H, SAM ZHOU H, MCMASTERS KM: Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol. Immunother. (2007) 56:997-1007.
  • STRBO N, YAMAZAKI K, LEE K, RUKAVINA D, PODACK ER: Heat shock fusion protein GP96-Ig mediates strong CD8 CTL expansion in vivo. Am. J. Reprod. Immunol. (2002) 48:220-225.
  • SENGUPTA D, NORRIS PJ, SUSCOVICH TJ et al.: Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J. Immunol. (2004) 173:1987-1993.
  • DOODY AD, KOVALCHIN JT, MIHALYO MA, HAGYMASI AT, DRAKE CG, ADLER AJ: Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J. Immunol. (2004) 172:6087-6092.
  • RAPP UK, KAUFMANN SH: DNA vaccination with GP96-peptide fusion proteins induces protection against an intracellular bacterial pathogen. Int. Immunol. (2004) 16:597-605.
  • TAMURA Y, PENG P, LIU K, DAOU M, SRIVASTAVA PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 278:117-120.
  • PARMIANI G, TESTORI A, MAIO M et al.: Heat shock proteins and their use as anticancer vaccines. Clin. Cancer Res. (2004) 10:8142-8146.
  • JANETZKI S, PALLA D, ROSENHAUER V, LOCHS H, LEWIS JJ, SRIVASTAVA PK: Immunization of cancer patients with autologous cancer-derived heat shock protein GP96 preparations: a pilot study. Int. J. Cancer (2000) 88:232-238.
  • BELLI F, TESTORI A, RIVOLTINI L et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein GP96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. (2002) 20:4169-4180.
  • RICHARDS J, TESTORI A, WHITMAN E et al.: Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized Phase III trial in stage IV melanoma. 2006 ASCO Annual Meeting Proceedings. Atlanta, USA (2006) (Abstract 8002).
  • PILLA L, PATUZZO R, RIVOLTINI L et al.: A Phase II trial of vaccination with autologous, tumor-derived heat shock protein peptide complexes GP96, in combination with GM-CSF and interferon-α in metastatic melanoma patients. Cancer Immunol. Immunother. (2006) 55:958-968.
  • MAZZAFERRO V, COPPA J, CARRABBA MG et al.: Vaccination with autologous tumor-derived heat shock protein GP96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. (2003) 9:3235-3245.
  • RIVOLTINI L, CASTELLI C, CARRABBA M et al.: Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J. Immunol. (2003) 171:3467-3474.
  • AMATO R, MURRAY L, WOOD L, SAVARY C, TOMASOVIC S, REITSMA D: Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor derived heat shock protein–peptide complex-96 (HSPP-96) vaccine. 1999 ASCO Annual Meeting Proceedings. Atlanta, USA (1999) (Abstract 1278).
  • ASSIKIS VJ, DALIANI D, PAGLIARO L et al.: Phase II study of an autologous tumor derived heat shock protein–peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). 2003 ASCO Annual Meeting Proceedings. Chicago, USA (2003) (Abstract 1552).
  • WOOD CG, ESCUDIER B, LACOMBE L et al.: A multicenter randomized Phase III trial of a novel autologous therapeutic vaccine (vitespen) vs observation adjuvant therapy in patients at high-risk of recurrence after nephrectomy for renal cell carcinoma (RCC). Proceedings of the 2007 AUA. Anaheim, CA, USA (2007) (Abstract 633).
  • OKI Y, MCLAUGHLIN P, FAYAD LE et al.: Experience with heat shock protein–peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer (2007) 109:77-83.
  • HUANG X, REN W, ROLLINS L et al.: A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res. (2005) 63:7321-7329.
  • WU Y, WAN T, ZHOU X et al.: Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine. Cancer Res. (2005) 65:4947-4954.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.